Vitrolife AB (publ) VITR
This picture changes. Follow Vitrolife AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Vitrolife AB (publ) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 18 Jul 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Hold if you own; consider adding only after further Q2 confirmation that Consumables/Technologies momentum persists and Genetics actions track to plan. Reduce only if your risk budget cannot tolerate ongoing FX/legal/execution risk.
Q1 provided the missing evidence on margin stabilization (gross margin ~60%) and cash-flow strength, while the Genetics restructuring adds a clear earnings lever into H2 2026. However, elevated risks remain from FX, geopolitical disruption (EMEA/Middle East), execution in Genetics, and US legal uncertainty (PGT-A).
Market sentiment
8/10
↑
Trend: Improving
Sentiment has improved further as Ferd’s increased ownership is seen as a confidence signal and the COO appointment may strengthen operational execution; however, the CEO departure adds clear uncertainty around strategy and delivery.
Risk assessment
8/10
Dilution:
Low
Positive cash flow and low net debt/EBITDA
Jurisdiction:
Medium
US exposure and ongoing PGT-A class action
Execution:
High
Genetic Services restructuring and product phase-outs
Recent changes
- Q2 showed weak organic growth (-1%) but strong profitability (gross margin 60.3%) and a 34.4% EBITDA margin. The board also approved a share buyback program of up to SEK 500m.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company freeAbout the company
Vitrolife AB (publ) is a medtech company supplying consumables, equipment and services to IVF clinics globally. The group includes genetic services via Igenomix and technologies such as EmbryoScope. FY2025 results were heavily impacted by large impairments and restructuring in Genetic Services.
Sector:
Medtech for IVF and reproductive health
Type:
Other
Next report
22 Oct 2026
Q3
Catalysts
22 Oct 2026
Permanent CEO appointment
High
Unknown
Outcome of US-related PGT-A litigation
High
Unknown
Execution of the buyback program
Medium
Horizon:
Bull case
The buyback program and demonstrated margin uplift from restructuring can support EPS even if growth remains muted.
Bear case
Weak organic growth and high execution risk in Genetics, alongside FX and US regulatory/legal risks, may continue to cap re-rating.
Signal rationale (informational)
Q1 provided the missing evidence on margin stabilization (gross margin ~60%) and cash-flow strength, while the Genetics restructuring adds a clear earnings lever into H2 2026. However, elevated risks remain from FX, geopolitical disruption (EMEA/Middle East), execution in Genetics, and US legal uncertainty (PGT-A).
Recent news
- The board has launched a share buyback program of up to SEK 500m starting 17 July 2026 and running until the 2027 AGM. The Q2 report (16 July) showed revenue of SEK 857m with weak organic development but clearly improved margins (gross margin 60.3% and EBITDA margin 34.4%), triggering a sharp share move followed by some pullback; Handelsbanken raised its target price to SEK 100 and reiterated hold.
Price & valuation
Last close
SEK 91.05
1 week
+3.4 %
3 months
-13.3 %
12 months
-32.8 %
From 52w high
-39.1 %
From 52w low
+7.3 %
Exchange
Stockholm
Sector
Medtech for IVF and reproductive health
This picture changes. Follow Vitrolife AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.